← FDA DRUG APPROVALS

FDA ANDA · ANDA209647

ESOMEPRAZOLE MAGNESIUM

Sponsor: AMNEAL PHARMS NY

APPLICATION
ANDA209647
TYPE
ANDA
ORIGINAL APPROVAL
2019-04-10
LATEST ACTION
2024-10-04
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Discontinued

Products

ESOMEPRAZOLE MAGNESIUMDiscontinued
ESOMEPRAZOLE MAGNESIUM EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
ESOMEPRAZOLE MAGNESIUMDiscontinued
ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL

Approval history

2024-10-04Labeling · Supplement 8 · standardAP
2023-05-22Labeling · Supplement 4 · standardAP
2023-05-22Labeling · Supplement 7 · standardAP
2023-05-22Labeling · Supplement 5 · standardAP
2019-04-10UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →